$7 million upfront with up to an additional$14.5 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrantsHENDERSON, Nev., Aug. 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into definitive agreements for the purchase and sale of 12,727,273 shares of its common stock (or common stock equivalents in lieu thereof) and milestone-linked warrants, ...